Comparative Pharmacology
Head-to-head clinical analysis: HYDROXYZINE versus KOVANAZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROXYZINE versus KOVANAZE.
HYDROXYZINE vs KOVANAZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors in the gastrointestinal tract, blood vessels, and respiratory tract. It also exhibits sedative, anxiolytic, and antiemetic properties, possibly through central nervous system depression and anticholinergic effects.
KOVANAZE (norepinephrine and phenylephrine) is a combination of two vasopressors: norepinephrine, an α1-adrenergic receptor agonist with β1-adrenergic activity, and phenylephrine, a selective α1-adrenergic receptor agonist. Both agents cause vasoconstriction and increase blood pressure via activation of α1-adrenergic receptors on vascular smooth muscle.
25-100 mg orally 3-4 times daily; 50-100 mg IM every 4-6 hours as needed. Maximum oral dose: 600 mg/day in divided doses.
Intravenous bolus of 1 mg/kg over 10 minutes, followed by intravenous infusion of 0.02 mg/kg/min for 4 hours, then 0.01 mg/kg/min for 20 hours.
None Documented
None Documented
Clinical Note
moderateHydroxyzine + Venlafaxine
"The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Venlafaxine."
Clinical Note
moderateHydroxyzine + Nefazodone
"The risk or severity of adverse effects can be increased when Hydroxyzine is combined with Nefazodone."
Clinical Note
moderateHydroxyzine + Mifepristone
"Hydroxyzine may increase the QTc-prolonging activities of Mifepristone."
Clinical Note
moderateHydroxyzine + Fesoterodine
Terminal elimination half-life: 14-25 hours (mean ~20 h). In elderly or hepatic impairment, may be prolonged; antihistamine effect persists beyond half-life due to active metabolite.
Terminal elimination half-life: approximately 7-9 hours following nasal administration; clinical significance: supports twice-daily dosing regimen
Renal: approximately 70% as metabolites, less than 1% unchanged. Fecal/biliary: minor. Cetirizine (active metabolite) also renally eliminated.
Renal excretion of unchanged drug: ~20-30%; fecal/biliary elimination: minimal (<5%); remainder as metabolites
Category A/B
Category C
Antihistamine
Antihistamine + Corticosteroid Combination
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyzine."